FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health (NASDAQ:JAGX) announced FDA approval renewal for Canalevia-CA1, their prescription drug treating chemotherapy-induced diarrhea (CID) in dogs. The renewal extends conditional approval until December 21, 2025. Canalevia-CA1, a canine-specific formulation of crofelemer derived from the Croton lechleri tree, remains the first and only FDA-approved treatment for CID in dogs. The company is progressing toward full FDA approval through an agreed-upon clinical field study design. The drug is currently available through major U.S. veterinary distributors, including Chewy.
Jaguar Health (NASDAQ:JAGX) ha annunciato il rinnovo dell'approvazione da parte della FDA per Canalevia-CA1, il loro farmaco su prescrizione per il trattamento della diarrea indotta da chemioterapia (CID) nei cani. Il rinnovo estende l'approvazione condizionale fino al 21 dicembre 2025. Canalevia-CA1, una formulazione specifica per cani di crofelemer derivato dall'albero Croton lechleri, rimane il primo e unico trattamento approvato dalla FDA per CID nei cani. La società sta avanzando verso l'approvazione completa della FDA attraverso un disegno concordato di studio clinico sul campo. Il farmaco è attualmente disponibile tramite i principali distributori veterinari statunitensi, inclusa Chewy.
Jaguar Health (NASDAQ:JAGX) anunció la renovación de la aprobación de la FDA para Canalevia-CA1, su medicamento recetado que trata la diarrea inducida por quimioterapia (CID) en perros. La renovación extiende la aprobación condicional hasta el 21 de diciembre de 2025. Canalevia-CA1, una formulación específica para perros de crofelemer derivado del árbol Croton lechleri, sigue siendo el primer y único tratamiento aprobado por la FDA para CID en perros. La empresa está avanzando hacia la aprobación completa de la FDA a través de un diseño de estudio clínico de campo acordado. El medicamento está actualmente disponible a través de los principales distribuidores veterinarios de EE. UU., incluyendo Chewy.
재규어 헬스 (NASDAQ:JAGX)는 개에서 화학요법 유발 설사를 치료하는 처방약 카날레비아-CA1에 대한 FDA 승인 갱신을 발표했습니다. 이번 갱신으로 조건부 승인은 2025년 12월 21일까지 연장됩니다. 카날레비아-CA1은 크로톤 레클레리 나무에서 유래한 크로페레머의 개 전용 제형으로, 개에서 CID에 대한 FDA 승인 치료법으로는 첫 번째이자 유일합니다. 이 회사는 합의된 임상 현장 연구 디자인을 통해 FDA의 완전 승인을 향해 나아가고 있습니다. 이 약물은 현재 Chewy를 포함한 미국의 주요 수의학 유통업체를 통해 이용할 수 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé le renouvellement de l'approbation de la FDA pour Canalevia-CA1, leur médicament sur ordonnance traitant la diarrhée induite par la chimiothérapie (CID) chez les chiens. Le renouvellement prolonge l'approbation conditionnelle jusqu'au 21 décembre 2025. Canalevia-CA1, une formulation spécifique aux chiens de crofelemer dérivée de l'arbre Croton lechleri, reste le premier et unique traitement approuvé par la FDA pour le CID chez les chiens. L'entreprise progresse vers l'approbation complète de la FDA grâce à un design d'étude clinique sur le terrain convenu. Le médicament est actuellement disponible par le biais des principaux distributeurs vétérinaires américains, y compris Chewy.
Jaguar Health (NASDAQ:JAGX) hat die Erneuerung der FDA-Zulassung für Canalevia-CA1 angekündigt, ihr verschreibungspflichtiges Medikament zur Behandlung von chemotherapiebedingtem Durchfall (CID) bei Hunden. Die Erneuerung verlängert die bedingte Zulassung bis zum 21. Dezember 2025. Canalevia-CA1, eine hundespezifische Formulierung von Crofelemer, das vom Croton lechleri-Baum abgeleitet ist, bleibt die erste und einzige von der FDA zugelassene Behandlung für CID bei Hunden. Das Unternehmen arbeitet auf die vollständige FDA-Zulassung hin, basierend auf einem vereinbarten Design für klinische Feldstudien. Das Medikament ist derzeit über die wichtigsten tierärztlichen Distributoren in den USA, einschließlich Chewy, erhältlich.
- Secured FDA renewal of conditional approval until December 21, 2025
- Maintains exclusive market position as only FDA-approved treatment for CID in dogs
- Product currently available through major distribution channels
- Agreement reached with FDA on clinical field study design for full approval
- Still operating under conditional approval, pending full FDA approval
- Additional clinical studies required for full approval, indicating ongoing expenses
Insights
The FDA renewal of Canalevia-CA1's conditional approval represents a significant milestone in the veterinary pharmaceutical market. This unique position as the first and only FDA-approved treatment for chemotherapy-induced diarrhea in dogs provides Jaguar Health with a protected market opportunity until December 2025.
The progress toward proving substantial evidence of effectiveness through an agreed-upon clinical field study design indicates a clear pathway to full approval. This regulatory clarity reduces development risk and strengthens the product's market position. However, with Jaguar's small market cap of
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA
By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree
SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the U.S. Food and Drug Administration (FDA) has approved renewal of Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy. The renewal for conditional approval is in effect until December 21, 2025.
"We're very pleased about receiving the conditional approval renewal from the FDA," said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. "Canalevia-CA1 is an important prescription drug for the veterinary community and the thousands of dogs experiencing CID. This extension was granted because we were able to demonstrate that the company is making active progress toward proving ‘substantial evidence of effectiveness' of Canalevia-CA1 for treatment of CID in dogs for full approval, as required. As announced, we have reached agreement with the FDA on the design and conduct of a clinical field study of Canalevia-CA1 for full approval of the product."
"Diarrhea is a highly neglected and unmet medical need in dogs and people undergoing cancer treatment," said Lisa Conte, Jaguar's president and CEO. "Jaguar is deeply committed to supporting the quality of life of people and animals undergoing cancer treatment."
About Conditional Approval and Full Approval
Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the "substantial evidence" standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving "substantial evidence of effectiveness" for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.
About Chemotherapy-induced Diarrhea (CID) in Dogs
According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost
Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.
Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.
About Canalevia®-CA1
Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a "small number" threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.
About Crofelemer
Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will conduct a clinical field study of Canalevia-CA1 to support full approval of the product for the treatment of CID in dogs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 "Cancer in Pets." American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets
2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
When does Jaguar Health's (JAGX) Canalevia-CA1 FDA conditional approval expire?
What is Canalevia-CA1 approved to treat for Jaguar Health (JAGX)?
Where can veterinarians purchase Jaguar Health's (JAGX) Canalevia-CA1?
Is Jaguar Health's (JAGX) Canalevia-CA1 the only FDA-approved treatment for CID in dogs?
